Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-2940094. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 known ✓ | P41146 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2940094 SCHEMBL30733351 | 1.00 | OPRL1 (1.00) | OPRL1 | |
| Ly-2940094 SCHEMBL1809569 | 0.99 | OPRL1 (0.98) | OPRL1 | |
| Ly-2940094 SCHEMBL1809568 | 0.99 | OPRL1 (0.98) | OPRL1 | |
| SCHEMBL1812056 | 0.92 | OPRL1 (0.86) | OPRL1 | |
| SCHEMBL1804849 | 0.91 | OPRL1 (0.87) | OPRL1 | |
| SCHEMBL1806640 | 0.91 | OPRL1 (0.87) | OPRL1 | |
| SCHEMBL1807561 | 0.91 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL1808639 | 0.91 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL1807026 | 0.91 | OPRL1 (0.83) | OPRL1 | |
| SCHEMBL1806064 | 0.91 | OPRL1 (0.83) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024088808-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2024-05-02 | — | — | WO | claimed |
| CN-116981450-A | Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders | 安泰赛普生物风投二代有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023164385-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164387-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| EP-2787995-B1 | SPIROTHIENOPYRAN-PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE | LILLY CO ELI (US) | 2016-08-17 | — | — | EP | claimed |
| US-9371335-B2 | Spirothienopyran-piperidine derivatives as ORL-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse | ELI LILLY AND COMPANY (US) | 2016-06-21 | — | — | US | claimed |
| US-20140309251-A1 | SPIROTHIENOPYRAN-PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE | ELI LILLY AND COMPANY (US) | 2014-10-16 | — | — | US | claimed |
| WO-2014022143-A1 | ORL-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY | ELI LILLY AND COMPANY (US) | 2014-02-06 | — | — | WO | claimed |
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | claimed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | claimed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | OPRL1 28/4885 |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | OPRL1 144/4885 |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | OPRL1 28/4885 |
| US-20140309251-A1 | SPIROTHIENOPYRAN-PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE | ADH1A, ADH1C, OPRD1 | OPRL1 5/4885 |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | OPRL1 28/4885 |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | OPRL1 28/4885 |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | OPRL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.